Brandenburg Kapital - News about SphingoTec GmbH
SphingoTec and Rivaara Labs announce multi-year exclusive distribution agreement
Hennigsdorf – March 2022. Rivaara Labs, one of the leading providers of molecular diagnostics and point-of-care technologies in India, has been granted exclusive rights by SphingoTec to market and distribute the Nexus IB10 platform and its rapid tests for innovative biomarkers on the Indian subcontinent.
SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers that support personalized medicine in intensive care. The biomarkers provide important, organ-specific information for monitoring acute disease progressions such as sepsis or acute renal failure. In doing so, they support clinical decisions with the aim of improving patient management.
Brandenburg Kapital GmbH has been supporting the company since 2018.
Read the full press release here:
For more information, please visit: www.brandenburg-kapital.de, www.sphingotec.com